Takeda reintegrates U.K. sales team; Philidor continues downsizing with layoffs;

@FiercePharma: Dechra's growth spurt continues with $6M acquisition of Mexican manufacturer. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Huge consumer med capacity coming online for Bayer in China as the economy tanks. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: $GSK vaccines head Slaoui says the company's vax and pharma businesses need each other--aka, no break-up, please | Follow @CarlyHFierce

> Takeda, which had its sales team in the U.K. under management by Ashfield Healthcare, is moving the group back under the Takeda fold. Story

> Specialty pharmacy Philidor Rx Services has dismissed 264 employees in the Phoenix area as it continues to wind down after its failed relationship with Valeant Pharmaceuticals ($VRX). Story

> India's Piramal Enterprises is reportedly in talks to sell a 20% stake in is over-the-counter business. Report

> Esteban Plata has been named vice president of Western Europe and Canada for AbbVie ($ABBV), replacing Pascale Richetta who is stepping down at the end of the month. Report

Medical Device News

@FierceMedDev: FDA makes increasing use of 'real-world' device data a strategic priority. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Heartware shares plunge on bad new about device trial. Article | Follow @VarunSaxena2

@EmilyWFierce: NIH urged to 'break taboo' against using its power to bypass drug patents. FiercePharma article | Follow @EmilyWFierce

> JPM: St. Jude plagued by gap in its portfolio of pacemakers and implantable defibrillators. Story

> NIH commits $313M over four years to sequencing genomics of human disease. Article

> Devices grab $2.7B in VC again, but that may weaken in 2016. Editor's corner

Biotech News

@FierceBiotech: Johns Hopkins flags another possible successor to 'Special K' for depression. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Did I say the eteplirsen data was messy? More from the FDA (PDF) | Follow @JohnCFierce

@DamianFierce: $MRK is mad about Merck, KGaA, Darmstadt, Germany, Earth's rebrand. More (PDF) | Follow @DamianFierce

> FDA delays decision on Heron's twice-rejected nausea drug. Report

> Sarepta shares crash on a harsh FDA review of Duchenne's drug. Article

> Biotech rehearses its 'difficult' second album at #JPM16. Editor's corner

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.